Tag Archives: NASDAQ:CLVS

Analysts Offer Insights on Healthcare Companies: Clovis Oncology (NASDAQ: CLVS), CytomX Therapeutics Inc (NASDAQ: CTMX) and Aslan Pharmaceuticals Ltd (NASDAQ: ASLN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clovis Oncology (CLVS – Research Report), CytomX Therapeutics Inc (CTMX – Research Report) and Aslan Pharmaceuticals Ltd (ASLN – Research Report) with

J.P. Morgan Keeps a Hold Rating on Clovis Oncology (CLVS)

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Clovis Oncology (CLVS – Research Report), with a price target of $27. The company’s shares closed on Friday at $14.78, close to its 52-week low

H.C. Wainwright Thinks Clovis Oncology’s Stock is Going to Recover

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology (CLVS – Research Report), with a price target of $36. The company’s shares closed yesterday at $16.36, close to its 52-week low of

Clovis Oncology (CLVS) Receives a Buy from Credit Suisse

In a report issued on May 13, Lorenzo Biasio from Credit Suisse maintained a Buy rating on Clovis Oncology (CLVS – Research Report), with a price target of $29. The company’s shares closed yesterday at $18.77. According to TipRanks.com, Biasio

H.C. Wainwright Keeps Their Buy Rating on Clovis Oncology (CLVS)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Clovis Oncology (CLVS – Research Report) today and set a price target of $237. The company’s shares closed on Friday at $23.48. According to TipRanks.com, White is a 5-star analyst

Clovis Oncology (CLVS) Gets a Hold Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Clovis Oncology (CLVS – Research Report) on April 2. The company’s shares closed on Friday at $25.67. According to TipRanks.com, Kasimov is a 3-star analyst with an average return of